---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-024517"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-05-20T12:00:35+00:00"
generated_at: "2026-05-20T12:07:22.015001+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharma reports peer-reviewed Telomir-Zn data showing survival benefit in Wilson's disease model

## Summary
- Telomir-Zn dose-dependently improved survival, reduced hepatic copper burden and liver injury biomarkers (ALT, AST, bilirubin) in zebrafish Wilson's disease model.
- Preclinical study published in Advances in Redox Research; demonstrates reductions in oxidative stress, ROS-Ca²⁺ amplification, and tissue degeneration.
- First peer-reviewed publication for Telomir-Zn in Wilson's disease; supports mechanism across copper-redox modulation and mitochondrial protection.
- Telomir-Zn already has FDA IND clearance for Phase 1/2 in Triple-Negative Breast Cancer (April 2026); new data further validates platform.

## SEC filing metadata
- accession: 0001493152-26-024517
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-05-20T12:00:35+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/0001493152-26-024517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226024517/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-024517
- JSON: https://secwatch.observer/filing/0001493152-26-024517.json
- Plain text: https://secwatch.observer/filing/0001493152-26-024517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.